Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy

Breast Cancer

Volumn 5, Issue 3, 1998, Pages 211-217

  O'Regan, Ruth M ^a   England, Gale M ^a   Macgregor, Jennifer I ^a   Yao, Kathy A ^a   Muenzner, Henry D ^a   Takei, Hiroyuki ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Endometrial cancer; Raloxifene; Tamoxifen; Toremifene

Indexed keywords

EID: 0344760840     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966699     Document Type: Review

References (49)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
2. Furr B J A, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984. (Pubitemid 14015738)
3. Rose C, Thorpe SM, Andersen KW, et al: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet i: 16-19, 1985. (Pubitemid 15160544)
4. Ribeiro G, Swindell R: The Christie Hospital Adjuvant Tamoxifen Trial; Status at 10 years. Br J Cancer 57:601-603, 1988.
5. Hubay CA, Pearson OH, Marshall JS, et al: Adjuvant therapy of stage II breast cancer; 48 month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1:77-82, 1981. (Pubitemid 12179418)
6. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Rev Endo Rel Cancer (October Supplement):49-55, 1978.
7. Jordan VC, Dix CJ, Allen KE: The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE eds, Adjuvant Therapy of Cancer II, Grune & Stratton Inc, Orlando, pp 19-26, 1979.
8. Jordan VC, Allen KE: Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239-251, 1980. (Pubitemid 10166691)
9. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens; Problems and potential for future clinical applications. Breast Cancer Res Treat 3(suppl):73-86, 1983. (Pubitemid 14127069)
10. Baum M, Brinkley DM, Dossett JA, et al: Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet ii: 450, 1983. (Pubitemid 13043465)
11. Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer; The Scottish Trial; Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet ii: 171-175, 1987.
12. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996.
13. Osborne CK, Hobbs K, Clark GM: Effects of estrogens and anti-estrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985. (Pubitemid 15161051)
14. Gottardis MM, Robinson SP, Jordan VC: Estradiolstimulated growth of MCF-7 tumors implanted in athymic mice; A model to study the tumoristatic action of tamoxifen. J Steroid Biochem 20:311-314, 1988.
15. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988.
16. Gottardis MM, Wagner RJ, Borden EC, et al: Differential ability of antiestrogens to stimulate breast cancer cell line (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765-4769, 1989. (Pubitemid 19213621)
17. Wolf DM, Langan-Fahey SM, Parker CJ, et al: Investigation of the mechanism of tamoxifenstimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 85:806-812, 1993. (Pubitemid 23150312)
18. Welshons WV, Jordan VC: Adaptation of estrogendependent MCF-7 cells to low estrogen (phenol redfree) culture. Eur J Cancer Clin Oncol 23:1935-1939, 1987. (Pubitemid 18013337)
19. Pink JJ, Jiang S-Y, Fritsch M, et al: An estrogenindependent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptorrelated protein. Cancer Res 55:2583-2590, 1995.
20. Jordan VC: The control of hormone-dependent breast cancer growth; Are we talking about estrogen alone? Eur J Cancer Clin Oncol 24:1245-1248, 1988.
21. Wakeling AE: Therapeutic potential of pure antiestrogens in the treatment of breast cancer. J Steroid Biochem Mol Biol 37:771-775, 1990.
22. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989. (Pubitemid 19207240)
23. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer. J Natl Cancer Inst 87:746-750, 1995.
24. Howell A, De Friend D, Robertson H, et al: Response to a specific antiestrogen (ICI 182, 780) in tamoxifenresistant breast cancer. Lancet 345:29-30, 1995.
25. Howell A, De Friend DJ, Robertson JF, et al: Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182, 780 in women with advanced breast cancer. Br J Cancer 74:300-306, 1996.
26. Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006-4010, 1984. (Pubitemid 14041629)
27. Gottardis MM, Robinson SP, Satyaswaroop PG, et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988. (Pubitemid 18061868)
28. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer; Ocurrence of new primary cancers. Lancet i: 117-120, 1989. (Pubitemid 19034031)
29. Assikis VJ, Jordan VC: Gynecological effects of tamoxifen and the association with endometrial cancer. Int J Gynaecol Obstet 49:241-257, 1995.
30. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32 A: 1464-1476, 1996. (Pubitemid 26279109)
31. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30 A: 1714-1721, 1994. (Pubitemid 24355494)
32. Phillips DH, Carmichael PL, Hewer A, et al: Activation of tamoxifen and its metabolite alphahydroxytamoxifen to DNA-binding products; Comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17:89-94, 1996. (Pubitemid 26091275)
33. Martin EA, Rich KJ, White IN, et al: 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995.
34. Carmichael PL, Ugwumadu AH, Neven P, et al: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479, 1996. (Pubitemid 26104004)
35. Hemminki K, Rajaniemi H, Lindahl B, et al: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377, 1996. (Pubitemid 26330442)
36. International Agency for Research on Cancer (IARC): Tamoxifen. IARC Monogr Eval Carcinog Risks Hum 66:253-365, 1996. (http://www.iarc.fr/preleases/ 111e.htm)
37. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 113:2556-2566, 1995.
38. Vogel CL, Shemano I, Schoenfelder J, et al: Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer. J Clin Oncol 11:345-350, 1993. (Pubitemid 23046827)
39. Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer; A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993. (Pubitemid 23107736)
40. Merimsky O, Inbar M, Kovner F, et al: Adjuvant tamoxifen; 5 year control of dormant disease. Eur J Cancer 32 A: 174, 1996.
41. Ebbs SR, Roberts J, Baum M: Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer; Preliminary communication. J Steroid Biochem 36:239, 1990. (Pubitemid 20222779)
42. Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53:4534-4541, 1993. (Pubitemid 23304376)
43. Jordan VC: Fourteenth Gaddum Memorial Lecture; A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507-517, 1993. (Pubitemid 23279253)
44. Jordan VC, Phelps E, Lindgren JU: Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35, 1987. (Pubitemid 18038542)
45. Gottardis MM, Jordan VC: Antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987. (Pubitemid 17108463)
46. Gottardis MM, Ricchio ME, Satyaswaroop P, et al: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192, 1990. (Pubitemid 20190116)
47. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997. (Pubitemid 27510100)
48. Jordan VC, MacGregor JI, Tonetti DA: Tamoxifen; From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporos Int 7 (S1):S52-57, 1997.
49. Jordan VC: Tamoxifen; The herald of a new era of preventive therapeutics. J Natl Cancer Inst 89:747-749, 1997. (Pubitemid 27242274)